prusogliptin
Small moleculeexperimental
Clinical trial activity
13 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 2012 (NCT01650324)
Timeline
Indications
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- dbpr108
- dbpr108
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07026968 | Phase 3 | Jun 20, 2025 | Yiling Pharmaceutical Inc. |
| NCT05150626 | Phase 1 | Dec 31, 2021 | Shijiazhuang Pharma Group (CSPC) |
| NCT05146869 | Phase 1 | Dec 15, 2021 | Beijing Anzhen Hospital, Shijiazhuang Pharma Group (CSPC) |
| NCT05072028 | Phase 1 | Oct 31, 2021 | Shijiazhuang Pharma Group (CSPC) |
| NCT05045313 | Phase 1 | Sep 30, 2021 | Shijiazhuang Pharma Group (CSPC) |
| NCT04859439 | Phase 1 | Jun 15, 2021 | Shijiazhuang Pharma Group (CSPC) |
| NCT04859426 | Phase 1 | Jun 9, 2021 | Shijiazhuang Pharma Group (CSPC) |
| NCT04859452 | Phase 1 | May 26, 2021 | Shijiazhuang Pharma Group (CSPC) |
| NCT04218734 | Phase 3 | Jan 31, 2020 | Shijiazhuang Pharma Group (CSPC) |
| NCT04161430 | Phase 3 | Jan 20, 2020 | Shijiazhuang Pharma Group (CSPC) |
| NCT04124484 | Phase 2 | Oct 17, 2017 | Shijiazhuang Pharma Group (CSPC) |
| NCT02163278 | Phase 1 | Jun 1, 2014 | Government of Taiwan |
| NCT01650324 | Phase 1 | Jul 1, 2012 | Government of Taiwan |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shijiazhuang Pharma Group (CSPC) | For profit | 10 | 10 | 3 | 2017 |
| Government of Taiwan | Government | 2 | 2 | 1 | 2012 |
| Beijing Anzhen Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Yiling Pharmaceutical Inc. | For profit | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1